Elevance Health reported Q2 Profit And Revenue, Sticks To Annual Guidance
Elevance Health reported Q2 Profit And Revenue, Sticks To Annual Guidance
Elevance Health Inc. (NYSE:ELV) reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.
Elevance Health Inc.（紐交所：ELV）報告了第二季度營收爲432億美元，同比下降0.4％，略高於430.5億美元的共識。
The decrease was driven by attrition in Medicaid membership, partially offset by higher premium yields reflecting the medical cost trend and growth in CarelonRx product revenue related to members served.
這種下降是由於醫療補助會員流失，部分抵消了醫療成本趨勢和 CarelonRx 產品收入增長所反映的更高保費收益所致。
Related: Morgan Stanley Says Elevance Health's Growth Attributed To Consistent Performance But Undervalued.
相關：摩根士丹利表示 Elevance Health 的增長歸因於一貫的表現，但估值被低估。
Premiums fell 3.2% to $35.42 billion, and product revenue rose 14% to $5.53 billion. Services fees increased 18% to $2.28 billion.
保費下降3.2％至354.2億美元，產品收入增長14％至55.3億美元。服務費增長18％，至22.8億美元。
"Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which underpin our long-term targets," said Gail Boudreaux, President and CEO.
“第二季度的業績反映了我們多樣化的業務和在我們行業動態時期的戰略計劃的謹慎執行的力量，因爲我們堅定地致力於改善人類的健康狀況。我們已謹慎維持全年展望，並對我們的健康福利和 Carelon 業務的盈利能力有信心，這是我們長期目標的基礎，”美國醫療保健管理公司（HMO）Elevance Health 的總裁兼CEO Gail Boudreaux表示。
Profit rose 24% to $2.3 billion, or $9.85 a share. Per-share adjusted earnings reached $10.12, beating consensus of $10.01.
利潤增長了24％，至23億美元，每股收益爲9.85美元。每股調整後的盈利達到10.12美元，超過了10.01美元的共識。
The benefit expense ratio was 86.3%, an improvement of 10 basis points, driven primarily by premium rate adjustments to cover medical cost trends in the Health Benefits business and disciplined commercial underwriting.
受健康福利業務中醫療成本趨勢的保費調整和商業覈保紀律的推動，受益費用比率爲86.3％，較去年同期提高了10個點子。
Medical membership totaled approximately 45.8 million, a decrease of 5% compared to the prior year quarter, driven by attrition in Medicaid business associated with eligibility redeterminations and footprint adjustments, primarily in the first quarter.
醫保會員總數約爲4580萬，與上年同期相比下降了5％，主要是由於資格重新確定和足跡調整導致醫療補助業務流失，主要發生在第一季度。
Medicaid enrollment dropped 23% to 9 million in the second quarter compared to 11.7 million a year ago.
第二季度醫療補助保險登記人數從去年同期的1170萬下降了23％至900萬。
These losses were partially offset by growth in Affordable Care Act health plans and commercial Employer Group fee-based membership.
這些損失部分抵消了 Affordable Care Act 健康計劃和商業僱主小組費用基礎的會員增長。
Reuters notes that Unlike rivals UnitedHealth Group Inc (NYSE:UNH) and Humana Inc (NYSE:HUM), Elevance is less exposed to government-backed Medicare Advantage plans for people aged 65 and older and banks more on commercial and Medicaid health plans.
路透社指出，與競爭對手美國聯合健康集團股份有限公司（NYSE：UNH）和Humana Inc（NYSE：HUM）不同，Elevance less 受政府支持的65歲及以上人群的 Medicare Advantage 計劃的影響，更依賴於商業和醫療補助健康計劃。
Operating revenue at its Carelon division was $13.3 billion, up by 10% year-over-year.
其 Carelon 部門的營業收入爲133億美元，同比增長10％。
Guidance: Elevance Health expects GAAP net income per diluted share of at least $34.05 in 2024 and reaffirms adjusted EPS guidance of at least $37.20 versus consensus Of $37.28.
指引：Elevance Health 預計 2024 年 GAAP 每股稀釋淨收益至少爲34.05美元，重申至少爲37.20美元的調整後每股收益指引，而共識爲37.28美元。